Cholangiocarcinoma Resource Center

PATHWAY DISRUPTORS

TOPAZ-1 Study Explores Potential Prognostic Factors of Overall Survival for Patients With Advanced Biliary Tract Cancer

11/17/2023

Aiwu Ruth He, MD, PhD, summarizes the phase 3 TOPAZ-1 study and discusses treatment approaches for patients with biliary tract cancer.

Aiwu Ruth He, MD, PhD,...

11/17/2023

Journal of Clinical Pathways

News

Real-World Evidence Study Reveals Improved Survival in Biliary Tract Cancer Through Molecular Targeted Treatments

11/17/2023

Emry Lloyd ;

The use of molecular profiling for targeted treatments has shown a significant improvement in survival outcomes for patients with biliary tract cancer, according to a new study based on real-world evidence.

The use of molecular profiling...

11/17/2023

Journal of Clinical Pathways

NUC-1031 Did Not Prolong Overall Survival for Patients With Advanced Biliary Tract Cancers

11/17/2023

Allison Casey ;

In a phase 3 study, the phosphoramidate transformation of gemcitabine, NUC-1031 plus cisplatin did not prolong the overall survival, compared with gemcitabine-cisplatin, among patients with advanced biliary tract cancer.

In a phase 3 study, the...

11/17/2023

Journal of Clinical Pathways

News

Zanidatamab Shows Promise for HER2-Positive, Unresectable Biliary Tract Cancer

11/17/2023

Allison Casey ;

Zanidatamab, a bispecific antibody targeting 2 distinct HER2 epitopes, demonstrates meaningful clinical benefit with a manageable safety profile among patients with refractory, HER2-positive unresectable, locally advanced or metastatic...

Zanidatamab, a bispecific...

11/17/2023

Journal of Clinical Pathways

News

FDA Approves Pembrolizumab in Combination with Chemotherapy for Biliary Tract Cancer

11/17/2023

Brandon Twyford ;

The Food and Drug Administration (FDA) has granted approval for the use of pembrolizumab in conjunction with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer (BTC). This decision, announced on...

The Food and Drug Administration...

11/17/2023

Journal of Clinical Pathways

PATHWAY DISRUPTORS

TOPAZ-1 Study Explores Potential Prognostic Factors of Overall Survival for Patients With Advanced Biliary Tract Cancer

11/17/2023

Aiwu Ruth He , MD, PhD;

Aiwu Ruth He, MD, PhD, summarizes the phase 3 TOPAZ-1 study and discusses treatment approaches for patients with biliary tract cancer.

Aiwu Ruth He, MD, PhD,...

11/17/2023

Journal of Clinical Pathways

News

Real-World Evidence Study Reveals Improved Survival in Biliary Tract Cancer Through Molecular Targeted Treatments

11/17/2023

Emry Lloyd ;

The use of molecular profiling...

11/17/2023

Journal of Clinical Pathways

NUC-1031 Did Not Prolong Overall Survival for Patients With Advanced Biliary Tract Cancers

11/17/2023

Allison Casey ;

In a phase 3 study, the...

11/17/2023

Journal of Clinical Pathways

News

Zanidatamab Shows Promise for HER2-Positive, Unresectable Biliary Tract Cancer

11/17/2023

Allison Casey ;

Zanidatamab, a bispecific...

11/17/2023

Journal of Clinical Pathways

News

FDA Approves Pembrolizumab in Combination with Chemotherapy for Biliary Tract Cancer

11/17/2023

Brandon Twyford ;

The Food and Drug Administration...

11/17/2023

Journal of Clinical Pathways

Videos

Future Directions in NSCLC Care: Navigating Pathways, Costs, and Cutting-Edge Therapies

11/14/2024

Sawsan Rashdan , MD;

Dr. Sawsan Rashdan, an associate professor at UT Southwestern Medical Center specializing in lung cancer, discusses the transformative impact of targeted therapies and immunotherapies on NSCLC treatment.

Dr. Sawsan Rashdan, an associate...

11/14/2024

Journal of Clinical Pathways

News

Enhancing Survival in Endometrial Cancer: Impact of Immunotherapy and Chemotherapy Combination Therapy

11/13/2024

Hannah Musick ;

Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...

Combining immunotherapy with...

11/13/2024

Journal of Clinical Pathways

News

Under 50% of Oncology Practices Offer Survivorship Clinics

11/12/2024

Jolynn Tumolo ;

Just 41% of oncology practice groups offer a general survivorship clinic for cancer survivors, according to a study published online in JNCI Cancer Spectrum.

Just 41% of oncology practice...

11/12/2024

Journal of Clinical Pathways

Videos

Evolving Oncology Pathways, CLL Treatment Advances, and the Role of Multidisciplinary Care Teams

11/12/2024

Shaffee Bacchus , PharmD;

Shaffee Bacchus, PharmD, discusses the evolution of oncology pathways, advancements in chronic lymphocytic leukemia (CLL) treatment, and the importance of multidisciplinary care teams in addressing comorbidities and enhancing patient quality...

Shaffee Bacchus, PharmD,...

11/12/2024

Journal of Clinical Pathways

Videos

Assessing Fixed-Duration Obinutuzumab, Ibrutinib, and Venetoclax in CLL: A 7-Year Follow-Up

11/08/2024

;

Kerry Rogers, MD, provides a 7-year update on her study that evaluated the progression-free survival and factors associated with undetectable minimal residual disease status after treatment with a fixed-duration combination of obinutuzumab,...

Kerry Rogers, MD, provides a...

11/08/2024

Journal of Clinical Pathways

News

Experts Reach Consensus on Myelofibrosis Management, Offering New Hope for Patients

11/08/2024

Lisa Kuhns , PhD, MD;

A comprehensive international consensus program has provided vital clinical recommendations to enhance the treatment landscape for myelofibrosis (MF).

A comprehensive international...

11/08/2024

Journal of Clinical Pathways

Conference Coverage

Oncology Pathways Research: Challenges, Adoption, and Future Trends

11/08/2024

Cindy Chen , MBA;

In an exclusive interview with the Journal of Clinical Pathways, Cindy Chen, Head of Research at HMP Market Access Insights, shares insights into the challenges, adoption, and future trends of oncology pathways research. Her discussion draws...

In an exclusive interview with...

11/08/2024

Journal of Clinical Pathways

Breaking Down Health Care

Navigating Payer Challenges in Cell and Gene Therapy

11/07/2024

Michael Kolodziej , MD;

John Hennessy , MBA;

In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the challenges and potential solutions for integrating cell and gene therapies—particularly CAR T—into clinical practice and insurance...

In this Breaking Down Health...

11/07/2024

Cancer Care Business Exchange

News

Advancing Personalized Treatment in Endometrial Cancer With the HECTOR Deep Learning Model

11/06/2024

Juliet Gallagher ;

According to a study published in Nature, endometrial cancer (EC) cases are on the rise, and 10% to 20% of patients with EC experience distant recurrence. In this study, in researchers aimed to predict distant recurrence of EC to improve...

According to a study published...

11/06/2024

Journal of Clinical Pathways

Videos

Navigating Multidisciplinary Care: Insights on Oncology Practice Integration and Pharmaceutical Partnerships

11/04/2024

John Hennessy , MBA;

John Hennessy, Principal at Valuate Health Consultancy, highlights the importance of multidisciplinary collaboration in oncology care to improve patient outcomes.

John Hennessy, Principal at...

11/04/2024

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways